Status:
TERMINATED
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Aventis Pharmaceuticals
Conditions:
Gram-Positive Bacterial Infections
Eligibility:
All Genders
27-16 years
Phase:
PHASE3
Brief Summary
Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokineti...
Eligibility Criteria
Inclusion
- Serious, suspected or documented gram-positive infection
Exclusion
- \-
Key Trial Info
Start Date :
June 1 2000
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00240747
Start Date
June 1 2000
End Date
January 1 2005
Last Update
May 25 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital
Oakland, California, United States, 94609
2
Children's Hospital of Orange County
Orange, California, United States, 92868
3
Duke University Medical Center
Durham, North Carolina, United States, 27705
4
Children's Hospital
Cincinnati, Ohio, United States, 45267